The inhibition of ADAM17 (GW280264X) in combination with cisplatin results in the synergistic inhibition of viability, and synergistic enhancement of apoptosis even occurs in primary tumor- and ascites-derived OvCa spheroids, thus being a promising target for future combinatorial treatments. This evidence concerns the gene ADAM17 and neoplasm.